Can Fite (Israel) Performance
| CANF Stock | 1.00 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Can Fite are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Can Fite Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Can Fite is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 8.3 M | |
| Total Cashflows From Investing Activities | -14.5 M |
Can |
Can Fite Relative Risk vs. Return Landscape
If you would invest 100.00 in Can Fite Biopharma on September 30, 2025 and sell it today you would earn a total of 0.00 from holding Can Fite Biopharma or generate 0.0% return on investment over 90 days. Can Fite Biopharma is generating negative expected returns and assumes 0.0% volatility on return distribution over the 90 days horizon. Simply put, 0% of stocks are less volatile than Can, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Can Fite Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Can Fite's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Can Fite Biopharma, and traders can use it to determine the average amount a Can Fite's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CANF |
Based on monthly moving average Can Fite is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Can Fite by adding Can Fite to a well-diversified portfolio.
Can Fite Fundamentals Growth
Can Stock prices reflect investors' perceptions of the future prospects and financial health of Can Fite, and Can Fite fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Can Stock performance.
| Return On Equity | -1.34 | |||
| Return On Asset | -0.5 | |||
| Operating Margin | (13.51) % | |||
| Current Valuation | 35.67 M | |||
| Shares Outstanding | 1.01 B | |||
| Price To Earning | (337.46) X | |||
| Price To Book | 2.84 X | |||
| Price To Sales | 85.87 X | |||
| Revenue | 853 K | |||
| EBITDA | (12.83 M) | |||
| Cash And Equivalents | 3.21 M | |||
| Cash Per Share | 0.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (9.86 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 20.25 M | |||
About Can Fite Performance
By analyzing Can Fite's fundamental ratios, stakeholders can gain valuable insights into Can Fite's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Can Fite has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Can Fite has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. CAN FITE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 7 people.Things to note about Can Fite Biopharma performance evaluation
Checking the ongoing alerts about Can Fite for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Can Fite Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Can Fite Biopharma generated a negative expected return over the last 90 days | |
| Can Fite Biopharma has some characteristics of a very speculative penny stock | |
| Can Fite Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 853 K. Net Loss for the year was (12.62 M) with profit before overhead, payroll, taxes, and interest of 853 K. | |
| Can Fite Biopharma has accumulated about 3.21 M in cash with (9.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07. |
- Analyzing Can Fite's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Can Fite's stock is overvalued or undervalued compared to its peers.
- Examining Can Fite's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Can Fite's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Can Fite's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Can Fite's stock. These opinions can provide insight into Can Fite's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |